Skip to main content
SpringerLink
Log in

Neurologic Manifestations of Systemic Rheumatologic Diseases

  • Chapter
  • First Online:
Clinical Neuroimmunology

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

As the field of autoimmune neurology develops, the role of the neurologist in the management of patients with systemic autoimmune disease is increasing. This chapter briefly reviews the neurologic manifestations, diagnostic approach, and treatment of neurosarcoidosis, IgG-4-related disease, Behçet syndrome, Sjögren syndrome, lupus, and rheumatoid arthritis. The neurologic manifestations of these conditions include parenchymal brain and brainstem disease, myelopathy, radiculopathy, myopathy, and all forms of peripheral neuropathy. Recognizing when a neurologic concern is related to immune-mediated or alternative mechanisms is a critical role for the neurologist as treatment decisions may be based on this assessment. Familiarity with the neurologic manifestations of systemic rheumatologic disease is therefore critical. The approach to treatment depends on the underlying mechanisms of disease and decisions should be made in consultation with other experts assisting in the clinical care of an individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lopez-Chiriboga AS, Clardy SL. Emerging subspecialties in neurology: autoimmune neurology. Neurology. 2017;89(11):e129–e33.

    Article  PubMed  Google Scholar 

  2. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305(4):391–9.

    Article  CAS  PubMed  Google Scholar 

  3. Rossi G, Cavazza A, Colby TV. Pathology of sarcoidosis. Clin Rev Allergy Immunol. 2015;49(1):36–44.

    Article  CAS  PubMed  Google Scholar 

  4. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49(7):1215–28.

    Article  CAS  Google Scholar 

  5. Ungprasert P, Carmona EM, Utz JP, Ryu JH, Crowson CS, Matteson EL. Epidemiology of sarcoidosis 1946–2013: a population-based study. Mayo Clin Proc. 2016;91(2):183–8.

    Article  PubMed  Google Scholar 

  6. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–65.

    Article  CAS  PubMed  Google Scholar 

  7. Iwai K, Tachibana T, Takemura T, Matsui Y, Kitaichi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. 1993;43(7–8):372–6.

    CAS  PubMed  Google Scholar 

  8. Krumholz A, Stern BJ. Neurologic manifestations of sarcoidosis. Handb Clin Neurol. 2014;119:305–33.

    Article  PubMed  Google Scholar 

  9. Oksanen V. Neurosarcoidosis: clinical presentations and course in 50 patients. Acta Neurol Scand. 1986;73(3):283–90.

    Article  CAS  PubMed  Google Scholar 

  10. Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis—diagnosis and management. QJM. 1999;92(2):103–17.

    Article  CAS  PubMed  Google Scholar 

  11. Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol. 2007;64(5):691–6.

    Article  PubMed  Google Scholar 

  12. Ferriby D, de Seze J, Stojkovic T, Hachulla E, Wallaert B, Destee A, et al. Long-term follow-up of neurosarcoidosis. Neurology. 2001;57(5):927–9.

    Article  CAS  PubMed  Google Scholar 

  13. Carlson ML, White JR Jr, Espahbodi M, Haynes DS, Driscoll CL, Aksamit AJ, et al. Cranial base manifestations of neurosarcoidosis: a review of 305 patients. Otol Neurotol. 2015;36(1):156–66.

    PubMed  Google Scholar 

  14. Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology. 2017;89(20):2092–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ungprasert P, Matteson EL. Neurosarcoidosis. Rheum Dis Clin N Am. 2017;43(4):593–606.

    Article  Google Scholar 

  16. Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM. 2009;102(7):449–60.

    Article  CAS  PubMed  Google Scholar 

  17. Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909–17.

    Article  CAS  PubMed  Google Scholar 

  18. Bagnato F, Stern BJ. Neurosarcoidosis: diagnosis, therapy and biomarkers. Expert Rev Neurother. 2015;15(5):533–48.

    Article  CAS  PubMed  Google Scholar 

  19. Bathla G, Watal P, Gupta S, Nagpal P, Mohan S, Moritani T. Cerebrovascular manifestations of neurosarcoidosis: an underrecognized aspect of the imaging spectrum. AJNR Am J Neuroradiol. 2018;39(7):1194–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Luke RA, Stern BJ, Krumholz A, Johns CJ. Neurosarcoidosis: the long-term clinical course. Neurology. 1987;37(3):461–3.

    Article  CAS  PubMed  Google Scholar 

  21. Ginat DT, Dhillon G, Almast J. Magnetic resonance imaging of neurosarcoidosis. J Clin Imaging Sci. 2011;1:15.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lury KM, Smith JK, Matheus MG, Castillo M. Neurosarcoidosis—review of imaging findings. Semin Roentgenol. 2004;39(4):495–504.

    Article  PubMed  Google Scholar 

  23. Murialdo G, Tamagno G. Endocrine aspects of neurosarcoidosis. J Endocrinol Investig. 2002;25(7):650–62.

    Article  CAS  Google Scholar 

  24. Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol. 2001;248(5):363–72.

    Article  CAS  PubMed  Google Scholar 

  25. Tyshkov C, Pawate S, Bradshaw MJ, Kimbrough DJ, Chitnis T, Gelfand JM, Ryerson LZ, Kister I. Multiple sclerosis and sarcoidosis: A case for coexistence. Neurol Clin Pract. 2019;9(3):218–27. PMID:31341709.

    Google Scholar 

  26. Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, et al. Neurosarcoidosis: presentations and management. Neurologist. 2010;16(1):2–15.

    Article  PubMed  Google Scholar 

  27. Spiegel DR, Morris K, Rayamajhi U. Neurosarcoidosis and the complexity in its differential diagnoses: a review. Innov Clin Neurosci. 2012;9(4):10–6.

    PubMed  PubMed Central  Google Scholar 

  28. Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol. 2004;3(7):397–407.

    Article  PubMed  Google Scholar 

  29. Joubert B, Chapelon-Abric C, Biard L, Saadoun D, Demeret S, Dormont D, et al. Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis. JAMA Neurol. 2017;74(11):1336–44.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Junger SS, Stern BJ, Levine SR, Sipos E, Marti-Masso JF. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology. 1993;43(2):333–7.

    Article  CAS  PubMed  Google Scholar 

  31. Cohen-Aubart F, Galanaud D, Grabli D, Haroche J, Amoura Z, Chapelon-Abric C, et al. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore). 2010;89(2):133–40.

    Article  Google Scholar 

  32. Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. AJR Am J Roentgenol. 2004;182(2):289–95.

    Article  PubMed  Google Scholar 

  33. Hashmi M, Kyritsis AP. Diagnosis and treatment of intramedullary spinal cord sarcoidosis. J Neurol. 1998;245(3):178–80.

    Article  CAS  PubMed  Google Scholar 

  34. Zalewski NL, Krecke KN, Weinshenker BG, Aksamit AJ, Conway BL, McKeon A, et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology. 2016;87(7):743–4.

    Article  PubMed  Google Scholar 

  35. Flanagan EP, Kaufmann TJ, Krecke KN, Aksamit AJ, Pittock SJ, Keegan BM, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol. 2016;79(3):437–47.

    Article  PubMed  Google Scholar 

  36. Zuniga G, Ropper AH, Frank J. Sarcoid peripheral neuropathy. Neurology. 1991;41(10):1558–61.

    Article  CAS  PubMed  Google Scholar 

  37. Heij L, Dahan A, Hoitsma E. Sarcoidosis and pain caused by small-fiber neuropathy. Pain Res Treat. 2012;2012:256024.

    PubMed  PubMed Central  Google Scholar 

  38. Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep. 2011;15(3):201–6.

    Article  PubMed  Google Scholar 

  39. Aubart FC, Abbara S, Maisonobe T, Cottin V, Papo T, Haroche J, Mathian A, Pha M, Gilardin L, Hervier B, Soussan M, Morlat P, Nunes H, Benveniste O, Amoura Z, Valeyre D. Symptomatic muscular sarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e443.

    Article  Google Scholar 

  40. Stern BJ, Royal W III, Gelfand JM, Clifford DB, Tavee J, Pawate S, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018;75(12):1546–53.

    Article  PubMed  Google Scholar 

  41. Dale JC, O’Brien JF. Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc. 1999;74(5):535.

    Article  CAS  PubMed  Google Scholar 

  42. Tahmoush AJ, Amir MS, Connor WW, Farry JK, Didato S, Ulhoa-Cintra A, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(3):191–7.

    PubMed  Google Scholar 

  43. Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol. 2015;285:1–3.

    Article  CAS  PubMed  Google Scholar 

  44. Ungprasert P, Carmona EM, Crowson CS, Matteson EL. Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: a population-based study. Lung. 2016;194(1):91–5.

    Article  CAS  PubMed  Google Scholar 

  45. Bathla G, Singh AK, Policeni B, Agarwal A, Case B. Imaging of neurosarcoidosis: common, uncommon, and rare. Clin Radiol. 2016;71(1):96–106.

    Article  CAS  PubMed  Google Scholar 

  46. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132(6):1949–53.

    Article  PubMed  Google Scholar 

  47. Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol. 1995;52(9):875–9.

    Article  CAS  PubMed  Google Scholar 

  48. Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16(1):220.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Bitoun S, Bouvry D, Borie R, Mahevas M, Sacre K, Haroche J, et al. Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology. 2016;87(24):2517–21.

    Article  CAS  PubMed  Google Scholar 

  50. Bradshaw MJ, Gelfand JM, Stern B, Clifford DB, Wang Y, Cho TA, Vu N, Sriram S, Moses H, Bagnato F, Koth LL, Hauser SL, Dierkhising J, Kaufmann JA, Ammah D, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S. Infliximab for the treatment of neurosarcoidosis: a multi-institutional case series. Neurology. 2017;88(16):Supplement P1.335.

    Google Scholar 

  51. Decock A, Van Assche G, Vermeire S, Wuyts W, Ferrante M. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohns Colitis. 2017;11(3):378–83.

    PubMed  Google Scholar 

  52. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–92.

    Article  PubMed  Google Scholar 

  53. AbdelRazek MA, Venna N, Stone JH. IgG4-related disease of the central and peripheral nervous systems. Lancet Neurol. 2018;17(2):183–92.

    Article  CAS  PubMed  Google Scholar 

  54. Lu LX, Della-Torre E, Stone JH, Clark SW. IgG4-related hypertrophic pachymeningitis: clinical features, diagnostic criteria, and treatment. JAMA Neurol. 2014;71(6):785–93.

    Article  PubMed  Google Scholar 

  55. Wu A, Andrew NH, McNab AA, Selva D. IgG4-related ophthalmic disease: pooling of published cases and literature review. Curr Allergy Asthma Rep. 2015;15(6):27.

    Article  PubMed  CAS  Google Scholar 

  56. Soussan JB, Deschamps R, Sadik JC, Savatovsky J, Deschamps L, Puttermann M, et al. Infraorbital nerve involvement on magnetic resonance imaging in European patients with IgG4-related ophthalmic disease: a specific sign. Eur Radiol. 2017;27(4):1335–43.

    Article  PubMed  Google Scholar 

  57. Ohyama K, Koike H, Takahashi M, Kawagashira Y, Iijima M, Watanabe H, et al. Immunoglobulin G4-related pathologic features in inflammatory neuropathies. Neurology. 2015;85(16):1400–7.

    Article  CAS  PubMed  Google Scholar 

  58. Stone JH, Brito-Zeron P, Bosch X, Ramos-Casals M. Diagnostic approach to the complexity of IgG4-related disease. Mayo Clin Proc. 2015;90(7):927–39.

    Article  CAS  PubMed  Google Scholar 

  59. Hao M, Liu M, Fan G, Yang X, Li J. Diagnostic value of serum IgG4 for IgG4-related disease: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2016;95(21):e3785.

    Article  CAS  Google Scholar 

  60. Mattoo H, Mahajan VS, Della-Torre E, Sekigami Y, Carruthers M, Wallace ZS, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol. 2014;134(3):679–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74(1):190–5.

    Article  CAS  PubMed  Google Scholar 

  62. Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688–99.

    Article  CAS  PubMed  Google Scholar 

  63. Ebbo M, Grados A, Samson M, Groh M, Loundou A, Rigolet A, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One. 2017;12(9):e0183844.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171–7.

    Article  CAS  PubMed  Google Scholar 

  65. Feigenbaum A. Description of Behcet’s syndrome in the Hippocratic third book of endemic diseases. Br J Ophthalmol. 1956;40(6):355–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Behçet H. Uber rezidivierende apthose durch ein virus verursachte gesuchwure am mund, am auge und an den genitalien. Dermatol Wochenschr. 1937;105:1152–7.

    Google Scholar 

  67. Gul A. Behcet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4(1):81–3.

    Article  PubMed  Google Scholar 

  68. Zhang M, Xu WD, Wen PF, Liang Y, Liu J, Pan HF, et al. Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet’s disease: an updated meta-analysis. Mol Vis. 2013;19:1913–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Siva A, Saip S. The spectrum of nervous system involvement in Behcet’s syndrome and its differential diagnosis. J Neurol. 2009;256(4):513–29.

    Article  PubMed  Google Scholar 

  70. Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behcet’s syndrome. Ann Rheum Dis. 1984;43(6):783–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Yazici H, Fresko I, Yurdakul S. Behcet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3(3):148–55.

    Article  PubMed  Google Scholar 

  72. Miller JJ, Venna N, Siva A. Neuro-Behcet disease and autoinflammatory disorders. Semin Neurol. 2014;34(4):437–43.

    Article  PubMed  Google Scholar 

  73. Al-Araji A, Kidd DP. Neuro-Behcet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204.

    Article  PubMed  Google Scholar 

  74. Houman MH, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M, et al. Behcet’s disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S58–64.

    CAS  PubMed  Google Scholar 

  75. Wechsler B, Vidailhet M, Piette JC, Bousser MG, Dell Isola B, Bletry O, et al. Cerebral venous thrombosis in Behcet’s disease: clinical study and long-term follow-up of 25 cases. Neurology. 1992;42(3 Pt 1):614–8.

    Article  CAS  PubMed  Google Scholar 

  76. Bradshaw MJ, Pawate S, Bloch KC, Moots P, Reddy NM. Clinical reasoning: a 52-year-old man with diplopia and ataxia. Neurology. 2016;87(13):e140–3.

    Article  PubMed  Google Scholar 

  77. Jubelt B, Mihai C, Li TM, Veerapaneni P. Rhombencephalitis/brainstem encephalitis. Curr Neurol Neurosci Rep. 2011;11(6):543–52.

    Article  CAS  PubMed  Google Scholar 

  78. International Team for the Revision of the International Criteria for Behcet’s Disease. The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.

    Article  Google Scholar 

  79. Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, et al. Diagnosis and management of Neuro-Behcet’s disease: international consensus recommendations. J Neurol. 2014;261(9):1662–76.

    Article  PubMed  Google Scholar 

  80. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287–96.

    Article  PubMed  CAS  Google Scholar 

  81. Saruhan-Direskeneli G, Yentur SP, Mutlu M, Shugaiv E, Yesilot N, Kurtuncu M, et al. Intrathecal oligoclonal IgG bands are infrequently found in neuro-Behcet’s disease. Clin Exp Rheumatol. 2013;31(3 Suppl 77):25–7.

    PubMed  Google Scholar 

  82. Scully SE, Stebner FC, Yoest SM. Magnetic resonance spectroscopic findings in neuro-Behcet disease. Neurologist. 2004;10(6):323–6.

    Article  PubMed  Google Scholar 

  83. Borhani Haghighi A, Sarhadi S, Farahangiz S. MRI findings of neuro-Behcet’s disease. Clin Rheumatol. 2011;30(6):765–70.

    Article  PubMed  Google Scholar 

  84. Albayram S, Saip S, Hasiloglu ZI, Teke M, Ceyhan E, Tutuncu M, et al. Evaluation of parenchymal neuro-Behcet disease by using susceptibility-weighted imaging. AJNR Am J Neuroradiol. 2011;32(6):1050–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Kao CH, Lan JL, ChangLai SP, Chieng PU. Technetium-99m-HMPAO SPECT and MRI of brain in patients with neuro-Behcet’s syndrome. J Nucl Med. 1998;39(10):1707–10.

    CAS  PubMed  Google Scholar 

  86. Hirohata S. Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Sci. 2008;267:41–7.

    Article  CAS  PubMed  Google Scholar 

  87. Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behcet’s syndrome. J Neurol Sci. 2008;272(1–2):99–105.

    Article  CAS  PubMed  Google Scholar 

  88. Borhani Haghighi A, Safari A, Nazarinia MA, Habibagahi Z, Shenavandeh S. Infliximab for patients with neuro-Behcet’s disease: case series and literature review. Clin Rheumatol. 2011;30(7):1007–12.

    Article  PubMed  Google Scholar 

  89. Sjögren H. Zur kenntnis der keratoconjunctivitis sicca (keratitis filiformis bei hypofunktion der tränendrüsen). Acta Ophthalmol. 1933;11(Suppl 2):1–151.

    Google Scholar 

  90. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Chai J, Logigian EL. Neurological manifestations of primary Sjogren’s syndrome. Curr Opin Neurol. 2010;23(5):509–13.

    Article  PubMed  Google Scholar 

  92. Gono T, Kawaguchi Y, Katsumata Y, Takagi K, Tochimoto A, Baba S, et al. Clinical manifestations of neurological involvement in primary Sjogren’s syndrome. Clin Rheumatol. 2011;30(4):485–90.

    Article  PubMed  Google Scholar 

  93. Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83(5):280–91.

    Article  Google Scholar 

  94. Berkowitz AL, Samuels MA. The neurology of Sjogren’s syndrome and the rheumatology of peripheral neuropathy and myelitis. Pract Neurol. 2014;14(1):14–22.

    Article  PubMed  Google Scholar 

  95. Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjogren’s syndrome-associated neuropathy. Brain. 2005;128(Pt 11):2518–34.

    Article  PubMed  Google Scholar 

  96. Margaretten M. Neurologic manifestations of primary Sjogren syndrome. Rheum Dis Clin N Am. 2017;43(4):519–29.

    Article  Google Scholar 

  97. Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, Callejas JL, Martinez-Berriotxoa A, Pallares L, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28(4):468–76.

    CAS  PubMed  Google Scholar 

  98. Bradshaw MJ, Kimbrough D. Neuromyelitis optica spectrum disorders. Pract Neurol. 2/2019. p. 76–89.

    Google Scholar 

  99. Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev. 2015;14(1):75–9.

    Article  CAS  PubMed  Google Scholar 

  100. Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A. 2006;103(52):19854–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol. 2013;4:484.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  102. Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin. 2010;28(1):61–73.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore). 1968;47(4):337–69.

    Article  CAS  Google Scholar 

  105. Ellison D, Gatter K, Heryet A, Esiri M. Intramural platelet deposition in cerebral vasculopathy of systemic lupus erythematosus. J Clin Pathol. 1993;46(1):37–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Timlin H, Petri M. Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus. 2013;22(12):1251–8.

    Article  CAS  PubMed  Google Scholar 

  107. Jafri K, Patterson SL, Lanata C. Central nervous system manifestations of systemic lupus erythematosus. Rheum Dis Clin N Am. 2017;43(4):531–45.

    Article  Google Scholar 

  108. Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology. 2005;64(12):2102–7.

    Article  PubMed  Google Scholar 

  109. Piga M, Chessa E, Peltz MT, Floris A, Mathieu A, Cauli A. Demyelinating syndrome in SLE encompasses different subtypes: do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun Rev. 2017;16(3):244–52.

    Article  PubMed  Google Scholar 

  110. Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry. 2006;77(3):290–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  111. Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 2009;60(11):3378–87.

    Article  CAS  PubMed  Google Scholar 

  112. Majed M, Fryer JP, McKeon A, Lennon VA, Pittock SJ. Clinical utility of testing AQP4-IgG in CSF: guidance for physicians. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):e231.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Pego-Reigosa JM, Cobo-Ibanez T, Calvo-Alen J, Loza-Santamaria E, Rahman A, Munoz-Fernandez S, et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2013;65(11):1775–85.

    Article  CAS  Google Scholar 

  114. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(4):620–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology. 2007;68(19):1614–7.

    Article  CAS  PubMed  Google Scholar 

  116. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470–5.

    Article  CAS  PubMed  Google Scholar 

  117. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38.

    Article  CAS  PubMed  Google Scholar 

  118. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.

    Article  PubMed  Google Scholar 

  119. Bhattacharyya S, Helfgott SM. Neurologic complications of systemic lupus erythematosus, Sjogren syndrome, and rheumatoid arthritis. Semin Neurol. 2014;34(4):425–36.

    Article  PubMed  Google Scholar 

  120. Dimberg EL. Rheumatology and neurology. Continuum (Minneap Minn). 2017;23(3, Neurology of Systemic Disease):691–721.

    Google Scholar 

  121. Agarwal V, Singh R, Wiclaf, Chauhan S, Tahlan A, Ahuja CK, et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol. 2008;27(7):841–4.

    Article  PubMed  Google Scholar 

  122. Yuh WT, Drew JM, Rizzo M, Ryals TJ, Sato Y, Bell WE. Evaluation of pachymeningitis by contrast-enhanced MR imaging in a patient with rheumatoid disease. AJNR Am J Neuroradiol. 1990;11(6):1247–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Bathon JM, Moreland LW, DiBartolomeo AG. Inflammatory central nervous system involvement in rheumatoid arthritis. Semin Arthritis Rheum. 1989;18(4):258–66.

    Article  CAS  PubMed  Google Scholar 

  124. Ramos M, Mandybur TI. Cerebral vasculitis in rheumatoid arthritis. Arch Neurol. 1975;32(4):271–5.

    Article  CAS  PubMed  Google Scholar 

  125. Bradshaw MJ, Cho TA, Chow FC. Central nervous system infections associated with immunosuppressive therapy for rheumatic disease. Rheum Dis Clin N Am. 2017;43(4):607–19.

    Article  Google Scholar 

  126. DeQuattro K, Imboden JB. Neurologic manifestations of rheumatoid arthritis. Rheum Dis Clin N Am. 2017;43(4):561–71.

    Article  Google Scholar 

  127. Ozkul A, Yilmaz A, Akyol A, Kiylioglu N. Cerebral vasculitis as a major manifestation of rheumatoid arthritis. Acta Clin Belg. 2015;70(5):359–63.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, Billings Clinic, Billings, MT, USA

    Michael J. Bradshaw

  2. Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA

    Shamik Bhattacharyya

  3. Neuro-Infectious Diseases, Harvard Medical School, Boston, MA, USA

    Nagagopal Venna

  4. Division of Neuroimmunology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

    Nagagopal Venna

  5. Rhode Island Hospital and Alpert Medical School of Brown University, Brown Neurology, Providence, RI, USA

    Jonathan F. Cahill

Authors
  1. Michael J. Bradshaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shamik Bhattacharyya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nagagopal Venna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonathan F. Cahill
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Rhode Island Hospital and Alpert Medical School of Brown University, Brown Neurology, Providence, RI, USA

    Syed A. Rizvi

  2. Rhode Island Hospital and Alpert Medical School of Brown University, Brown Neurology, Providence, RI, USA

    Jonathan F. Cahill

  3. Department of Neurology, MS Comprehensive Care Center, Stony Brook University Medical Center, Stony Brook, NY, USA

    Patricia K. Coyle

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bradshaw, M.J., Bhattacharyya, S., Venna, N., Cahill, J.F. (2020). Neurologic Manifestations of Systemic Rheumatologic Diseases. In: Rizvi, S., Cahill, J., Coyle, P. (eds) Clinical Neuroimmunology. Current Clinical Neurology. Humana, Cham. https://doi.org/10.1007/978-3-030-24436-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-24436-1_17

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-24435-4

  • Online ISBN: 978-3-030-24436-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation